{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead
Zentalis Pharmaceuticals, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential shift in market sentiment. Current indicators reflect a bearish outlook, with significant declines over the past year and challenges in the competitive market, despite a brief one-day performance increase.
Zentalis Pharmaceuticals Forms Golden Cross, Signaling Bullish Breakout Ahead
Zentalis Pharmaceuticals has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock rose significantly today and over the past week, despite a challenging year-to-date performance. Technical indicators suggest a bullish outlook, prompting interest in the company's future trends and recovery potential.
Is Zentalis Pharmaceuticals, Inc. technically bullish or bearish?
As of September 8, 2025, Zentalis Pharmaceuticals, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly year-to-date and over the past year.
Is Zentalis Pharmaceuticals, Inc. overvalued or undervalued?
As of May 7, 2024, Zentalis Pharmaceuticals is considered risky and overvalued due to significant losses and poor performance metrics, with a year-to-date return of -50.83%, compared to the S&P 500's 12.22%.
Is Zentalis Pharmaceuticals, Inc. overvalued or undervalued?
As of May 7, 2024, Zentalis Pharmaceuticals is considered "risky" and overvalued due to significant losses, reflected in its low valuation multiples and negative P/E ratio, while underperforming the S&P 500 with a year-to-date return of -57.1%.
Is Zentalis Pharmaceuticals, Inc. technically bullish or bearish?
As of May 1, 2025, the trend is mildly bearish due to daily moving averages indicating bearish momentum, despite a mildly bullish weekly MACD and a bullish monthly RSI, while overall indicators suggest weakness and significant underperformance compared to the S&P 500.
Who are in the management team of Zentalis Pharmaceuticals, Inc.?
As of March 2022, Zentalis Pharmaceuticals, Inc.'s management team includes Dr. Anthony Sun as Executive Chairman, President, and CEO, along with Directors Mr. Cam Gallagher and Independent Directors Dr. Kimberly Blackwell, Mr. David Johnson, and Mr. Karan Takhar.
What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for cancer. It has a market cap of approximately $107.93 million and reported a net profit loss of $48 million as of March 2025.
How big is Zentalis Pharmaceuticals, Inc.?
As of Jun 18, Zentalis Pharmaceuticals, Inc. has a market capitalization of 107.93 million, with net sales of 26.86 million and a net profit of -224.19 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
